JP2006506989A - 肺炎球菌感染を治療または予防するための組成物および方法 - Google Patents

肺炎球菌感染を治療または予防するための組成物および方法 Download PDF

Info

Publication number
JP2006506989A
JP2006506989A JP2004551863A JP2004551863A JP2006506989A JP 2006506989 A JP2006506989 A JP 2006506989A JP 2004551863 A JP2004551863 A JP 2004551863A JP 2004551863 A JP2004551863 A JP 2004551863A JP 2006506989 A JP2006506989 A JP 2006506989A
Authority
JP
Japan
Prior art keywords
immune response
polypeptide
seq
expression vector
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004551863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506989A5 (https=
Inventor
チェン，ミッチェル，シー．
チョウ，チュアン−ジウン
リー，ジョンミン
チェン，ドン−シェン
Original Assignee
シナジー アメリカ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナジー アメリカ，インコーポレイテッド filed Critical シナジー アメリカ，インコーポレイテッド
Publication of JP2006506989A publication Critical patent/JP2006506989A/ja
Publication of JP2006506989A5 publication Critical patent/JP2006506989A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004551863A 2002-11-07 2003-11-06 肺炎球菌感染を治療または予防するための組成物および方法 Pending JP2006506989A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07
PCT/US2003/035529 WO2004043376A2 (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009253536A Division JP2010057501A (ja) 2002-11-07 2009-11-04 肺炎球菌感染を治療または予防するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2006506989A true JP2006506989A (ja) 2006-03-02
JP2006506989A5 JP2006506989A5 (https=) 2008-08-21

Family

ID=32312819

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004551863A Pending JP2006506989A (ja) 2002-11-07 2003-11-06 肺炎球菌感染を治療または予防するための組成物および方法
JP2009253536A Pending JP2010057501A (ja) 2002-11-07 2009-11-04 肺炎球菌感染を治療または予防するための組成物および方法
JP2012025451A Pending JP2012139221A (ja) 2002-11-07 2012-02-08 肺炎球菌感染を治療または予防するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009253536A Pending JP2010057501A (ja) 2002-11-07 2009-11-04 肺炎球菌感染を治療または予防するための組成物および方法
JP2012025451A Pending JP2012139221A (ja) 2002-11-07 2012-02-08 肺炎球菌感染を治療または予防するための組成物および方法

Country Status (10)

Country Link
US (2) US7217791B2 (https=)
EP (1) EP1558280B1 (https=)
JP (3) JP2006506989A (https=)
KR (1) KR20050086427A (https=)
CN (1) CN100443116C (https=)
AU (1) AU2003291365B2 (https=)
CA (1) CA2504938C (https=)
ES (1) ES2451620T3 (https=)
TW (1) TWI315986B (https=)
WO (1) WO2004043376A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
EP2764093B1 (en) * 2011-10-05 2018-04-18 The Rockefeller University Dimeric bacteriophage lysins
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP4501949A3 (en) 2014-11-21 2025-04-30 The Board of Regents of the University of Oklahoma Pneumolysin mutants and methods of use thereof
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503948A (ja) * 1988-12-16 1992-07-16 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
JPH10504717A (ja) * 1994-08-24 1998-05-12 アメリカン・サイアナミド・カンパニー 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類
JP2001510031A (ja) * 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ES2258987T3 (es) * 1999-12-17 2006-09-16 Wyeth Holdings Corporation Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503948A (ja) * 1988-12-16 1992-07-16 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
JPH10504717A (ja) * 1994-08-24 1998-05-12 アメリカン・サイアナミド・カンパニー 肺炎双球菌感染症に対する免疫化のための肺炎双球菌多糖−組み換えニューモリシン結合体ワクチン類
JP2001510031A (ja) * 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009039579, ＦＥＭＳ Ｍｉｃｒｏｂｉｏｌ． Ｌｅｔｔ．, 1994, Ｖｏｌ． １２１, ｐ． ２１７−２２２ *
JPN6009039580, Ｉｎｆｅｃｔ． Ｉｍｍｕｎ．, 1996, Ｖｏｌ． ６４， Ｎｏ． ２, ｐ． ４８０−４８４ *

Also Published As

Publication number Publication date
US20080199952A1 (en) 2008-08-21
CN100443116C (zh) 2008-12-17
WO2004043376A2 (en) 2004-05-27
JP2010057501A (ja) 2010-03-18
EP1558280A2 (en) 2005-08-03
CN1711105A (zh) 2005-12-21
TW200418502A (en) 2004-10-01
CA2504938A1 (en) 2004-05-27
US7585669B2 (en) 2009-09-08
WO2004043376A3 (en) 2004-10-14
CA2504938C (en) 2011-10-11
JP2012139221A (ja) 2012-07-26
AU2003291365B2 (en) 2009-06-11
EP1558280A4 (en) 2007-08-29
AU2003291365A1 (en) 2004-06-03
US20040213803A1 (en) 2004-10-28
KR20050086427A (ko) 2005-08-30
ES2451620T3 (es) 2014-03-28
EP1558280B1 (en) 2014-01-08
HK1074005A1 (en) 2005-10-28
TWI315986B (en) 2009-10-21
US7217791B2 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
US9056912B2 (en) Immunogenic compositions for Streptococcus pyogenes
US7960535B2 (en) Recombinant lipidated PsaA protein, methods of preparation and use
US20180140666A1 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
JP2013215197A (ja) 免疫原性組成物
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
CN110845587A (zh) 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2017096374A1 (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
JP2015521618A (ja) ストレプトコッカス・ニューモニエによる肺炎に対するキメラタンパク質ワクチン
US20150079132A1 (en) Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
JP2012510289A (ja) グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
JP2015509713A (ja) 線毛タンパク質および組成物
JP2022508713A (ja) ワクチンポリペプチド組成物および方法
EP0502016B1 (en) Novel vaccine
HK1074005B (en) Compositions and methods for treating or preventing pneumococcal infection
AU2003204215B2 (en) Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
HK1004569B (en) Novel vaccine

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100421

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120420

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120425